---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000137"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-08-02T23:59:59+00:00"
generated_at: "2026-05-31T13:31:10.914766+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma promotes Kevin McCulloch to President and COO

## Summary
- Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.
- McCulloch will receive an annual base salary of $520,000 and a target annual incentive of 50% of base salary.
- He was granted 150,000 restricted stock units vesting over 3 years and 200,000 stock appreciation rights vesting at 2 years.
- Severance includes 1.25x salary plus target incentive if terminated without cause, or 1.5x if within 12 months after a change in control.
- McCulloch reports to CEO John Shannon and joined Xeris in 2018 as SVP of Global Operations and Business Development.

## SEC filing metadata
- accession: 0001867096-24-000137
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-08-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/0001867096-24-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/xers-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000137
- JSON: https://secwatch.observer/filing/0001867096-24-000137.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000137.txt

## Key facts
- Executive change
  Kevin McCulloch changed role as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..
  - Action: promoted
  - Role: President and Chief Operating Officer
  source text: The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/0001867096-24-000137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.